ArticleTuberculosis and respiratory diseases2026
Nationwide Incidence and Prevalence of Idiopathic Pulmonary Fibrosis in South Korea.
Article in Tuberculosis and respiratory diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundIdiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease with high mortality. Population-based data on long-term epidemiological trends and real-world treatment outcomes in Asia remain limited. This study described national trends in IPF prevalence and incidence in South Korea and evaluated pirfenidone use and associated mortality.
methodsUsing the Korean National Health Insurance Service customized research database, we identified prevalent IPF cases from 2010 to 2023 and incident cases from 2011 to 2023. IPF was defined using the International Classification of Diseases, 10th Revision, and rare intractable disease codes, based on a predefined operational definition. Among incident cases, the association between pirfenidone use and all-cause mortality was assessed using multivariable-adjusted Cox proportional hazards models.
resultsA total of 91,638 prevalent and 28,683 incident IPF cases were identified during the study period. The crude prevalence increased from 8.91 per 100,000 persons ≥50 years in 2010 to 63.78 per 100,000 in 2023. The crude incidence increased from 6.07 per 100,000 in 2011 to 16.86 per 100,000 in 2023. Similar increasing patterns were observed for age- and sex-standardized rates. IPF was more common in men, and demonstrated a pronounced age gradient. Following reimbursement approval, pirfenidone use increased substantially. Pirfenidone use was associated with a reduced risk of all-cause mortality (adjusted hazard ratio, 0.627; 95% confidence interval, 0.600 to 0.655), with progressively stronger associations observed with longer treatment duration.
conclusionThe burden of IPF in South Korea has increased over the past decade, during which expanded real-world pirfenidone use was associated with improved survival.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.